Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types

J Baselga, D Rischin, M Ranson, H Calvert, E Raymond, D G Kieback, S B Kaye, L Gianni, A Harris, Thomas Björk, S D Averbuch, A Feyereislova, H Swaisland, F Rojo, J Albanell

Research output: Contribution to journalArticlepeer-review

763 Citations (SciVal)

Fingerprint

Dive into the research topics of 'Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types'. Together they form a unique fingerprint.

Medicine & Life Sciences